Background Medium vessel occlusions (MeVOs) account for 25–40% of acute ischemic stroke. The Tenzing 5 (Route 92 Medical, San Mateo, California, USA) and FreeClimb 54 (Route 92 Medical, San Mateo, ...

Overview of Plasmapheresis MarketThe Global Plasmapheresis Market is valued at USD 1.34 Billion in 2024 and is projected to ...

Real-World U.S. Physician Preference Data1 Demonstrates the SOFIA™ 88 Catheter's Trackability, Atraumatic Design, and Overall Performance in Stroke Procedures NASHVILLE, Tenn., July 14, 2025 ...

Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 ...

Terumo Neuro Unveils New SOFIA™ 88 Catheter Data Demonstrating Strong Performance Compared to Other Super-Bore Catheters Provided by PR Newswire Jul 14, 2025, 6:00:00 AM ...

"These real-world results further validate SOFIATM 88 catheter's position as a leading super-bore support catheter," said Carsten Schroeder, President and CEO of Terumo Neuro. "This new dataset ...

/PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the commercial ...

Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships.

Terumo Neuro's SOFIA ™ Catheter Line is Backed By 10 Years of Proven Clinical Performance1-9 and Innovation – The New SOFIA™ Flow 88 Offers Reliable Trackability, Proximal Stability and ...